Tango Therapeutics financials
$24.42+0.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M |
| Gross profit | $62.4M | $42.1M | $36.5M | $24.9M | $37.0M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$111.3M | -$145.6M | -$114.2M | -$111.1M | -$58.2M |
| Net income | -$101.6M | -$130.3M | -$101.7M | -$108.2M | -$58.2M |
| Net margin | −162.9% | −309.7% | −278.5% | −435.1% | −157.2% |
| Diluted EPS | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 |
| EBITDA | -$109.0M | -$143.1M | -$111.8M | -$109.5M | -$57.3M |
| Operating cash flow | -$138.9M | -$131.5M | -$118.0M | -$109.1M | -$59.5M |
| Free cash flow | -$139.9M | -$132.3M | -$119.5M | -$116.8M | -$61.4M |
| Diluted shares | 116.2M | 109.2M | 94.6M | 87.8M | 62.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $112.3M | $69.5M | $66.4M | $60.0M | $142.7M |
| Short-term investments | $230.9M | $188.4M | $270.5M | $306.2M | $342.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $398.7M | $316.5M | $402.6M | $436.5M | $500.2M |
| Total liabilities | $52.5M | $117.0M | $149.5M | $187.0M | $155.4M |
| Shareholders' equity | $346.2M | $199.5M | $253.1M | $249.5M | $344.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology